We aimed to evaluate patients with upper extremity deep vein thrombosis (UEDVT) in terms of the risk factors, symptoms, clinical course, diagnostic approaches and treatment outcome. Thirty-six patients with a diagnosis of UEDVT, comprising 19 males (52.7%) and 17 females (47.3%), were included in the study; the mean (± SD) age was 54 ± 12.3 years. The most common risk factor was central venous catheter use. The treatment protocol consisted of low molecular weight heparin for up to 7 days, followed by oral anticoagulants for up to 6 months. All patients were followed up for 1 year. More than 90% of the patients responded well to treatment. Nine patients (25%) died due to underlying diseases; no patients died secondary to UEDVT. None of the patients developed pulmonary embolus or recurrent deep venous thrombosis, and post-thrombotic syndrome was not observed. The mortality rate was related to the underlying diseases.
Introduction
Upper extremity deep venous thrombosis (UEDVT) was initially described by Paget in 1875 and Schrotter in 1884 1 and constitutes approximately 1 -4% of all episodes of deep venous thrombosis (DVT). The most common risk factor for UEDVT is central venous catheterization; 2 other important risk factors include mediastinal tumours, lung cancer, hypertension, hypercoagulability, excessive effort, intravenous drug abuse, trauma, hormone and steroid usage, obesity, thoracic outlet syndrome and radiation. Behçet's disease, systemic lupus erythematosus and fibrosing mediastinitis may also play a role in the aetiology of venous occlusion. 1, 3, 4 UEDVT has a benign clinical course compared with lower extremity DVT, but possible early complications include pulmonary embolism and secondary arterial occlusion. Later post-thrombophlebitic syndrome may occur if the condition is not treated correctly. 3, 5 Contrast-enhanced venography remains an important diagnostic tool, but due to its high cost and invasiveness, utilization is limited. Colour Doppler ultrasonography (CDUSG) is a non-invasive and accurate alternative to venography. 6 The goal of therapy for UEDVT is relief of symptoms, enabling the patient to return to daily activities, and the avoidance of recurrences. It is important to choose the most advantageous treatment with regard to both the period of treatment and cost. 5, 7 The frequency of UEDVT has increased markedly in recent years due to increased use of invasive vascular procedures. This study evaluated patients with UEDVT in terms of the risk factors, symptoms, clinical course, diagnostic approaches and treatment outcomes.
Patients and methods

PATIENTS
Patients with a diagnosis of UEDVT admitted to the Heart and Vascular Surgery Clinic of Izmir Alsancak State Hospital, Izmir, Turkey, between July 1998 and July 2002 were included in the study. The diagnosis was based on medical history and physical examination, and was confirmed using CDUSG.
There is no ethical committee at the centre where the study was carried out so ethical approval could not be sought. On admission to the hospital, patients gave informed written consent for therapeutic procedures, including general, non-specific therapeutic management.
INVESTIGATIONS
Blood samples were taken before anticoagulation treatment to measure protein S, protein C and antithrombin III levels, and resistance to activated protein C, to determine whether hypercoagulation was present. A chest X-ray and perfusion scintigraphy were performed in all patients, followed by ventilation scintigraphy if signs of pulmonary embolus were seen. In addition, venography was performed in those patients who had no contraindications for this procedure.
DRUG THERAPY
All patients were treated with the low molecular weight heparin (LMWH) nadroparin calcium (Fraxiparine ® , Sanofi, Paris, France) subcutaneously twice a day at a dose of 86 anti-Xa IU/kg every 12 h. Oral anticoagulant treatment with warfarin sodium (Coumadin ® , Eczacibaşi, Istanbul, Turkey) was started on day 3 in all patients except those diagnosed with malignancy. The international normalized ratio (INR) value was maintained between 2 and 2.5. Nadroparin calcium was given to patients with malignancy for 10 days and warfarin sodium treatment was started on day 7. The INR follow-up period was generally shorter for patients with malignancy compared with those without. Additional medical treatments, including antibiotics, venoproteolytics, anti-aggregants and topical eau de Goulard, were used as necessary. CDUSG was repeated after at least 10 days to evaluate the treatment efficacy. All patients were followed in the out-patient clinic at 2-month intervals.
Results
A total of 36 patients with a diagnosis of UEDVT were included in the study. Of these, 19 (52.7%) were male and 17 (47.3%) were female. The mean (± SD) age was 54 ± 12.3 years (range 21 -70 years). The main complaints on admittance were swelling, pain, functional impairment of the upper extremity, mottled skin and visualization of venous collaterals around the shoulder joint. Localized warmth and erythema were observed in cases admitted to hospital during the early stages of the thrombosis.
All patients had an underlying disease (Table 1) , eight (22.2%) were hospitalized and 28 (77.8%) were followed in the outpatient clinic. None of the patients had a deficiency of protein C or protein S, or evidence of hypercoagulopathy syndrome on haematological testing. Lower extremity DVT was not present in any case.
The locations of the thrombosed venous segments seen on CDUSG are presented in Table 2 . Jugular vein thrombosis accompanied the UEDVT in three patients. In six cases, a thrombosed venous cord was palpable in the neck, axillary or supraclavicular area. UEDVT was demonstrated on the right side in 16 (44.4%) and on the left side in 20 (55.6%) patients. Bilateral thrombosis was not seen in any of the cases.
A chest X-ray and perfusion scintigraphy were performed in all patients. Since none of the perfusion scintigraphy examinations revealed any sign of pulmonary embolus, ventilation scintigraphy was not required. 
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Seven patients did not have contraindications for venographical examination; the presence of collateral veins was demonstrated on venography in all seven cases, confirming the diagnosis of thrombosis. In two of the three patients with jugular vein thrombosis, the occlusion could not be clearly demonstrated, since venography was performed solely in the upper extremity and the jugular veins were only visible due to reflux.
The median duration of nadroparin treatment was 6 days (range 4 -7 days). Warfarin treatment was continued for a mean (± SD) of 4.7 ± 1.2 months (range 3 -6 months). Patients were followed for a mean (± SD) of 12.2 ± 3.1 months (range 9 -15 months).
Recurrent thrombosis was not observed in any of the patients during the first 7 days of treatment, and symptomatic relief was achieved in 32 (88.8%) patients. The results of repeat CDUSG, performed after 10 -14 days, are given in Table 3 . Patients in whom the thrombus persisted throughout warfarin treatment did not have a history of malignancy.
No deaths occurred secondary to the UEDVT, but nine (25%) patients died before completing the follow-up period due to underlying disease. Of these, five (13.8%) had malignancies (lung carcinoma, 2; breast carcinoma, 2; and carcinoma of the colon, 1), three had chronic renal impairment (UEDVT due to subclavian catheter), and one had coronary heart disease and died of a myocardial infarction (UEDVT due to peripheral venous route usage). During the follow-up period, none of the patients developed post-phlebitic syndrome.
Discussion
Pain, swelling and functional impairment of the upper extremity usually occur in UEDVT, but rarely may it be totally asymptomatic. The most typical characteristic of UEDVT on physical examination is non-pitting oedema. Erythema and warmth of the upper extremity and shoulder can also be observed during the early stages. A tender venous cord may be palpated along the axillary, subclavian or jugular veins. 5, 8, 9 Pain and swelling of the upper extremity were present in all of the cases in our study.
The pathogenesis of thrombosis in UEDVT, as described in Virchow's classical triad, is related to hypercoagulability, changes in the intima and stasis. The intrinsic coagulation chain is activated directly: release of thromboplastic substances damages the intima, initiating the coagulation process, and thrombocytes adhere to the basal membrane in the damaged area, leading to the release of factors that increase coagulation. 1 Subclavian catheters not only 
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traumatize veins but also cause an increase in turbulence by changing the venous flow, leading to thrombocyte aggregation. Localized thrombus is formed and procoagulants are released, and this leads to a further decrease in the blood flow and even total occlusion of the vessel. In addition, single intravenous interventions for drug infusion or drawing blood may lead to thrombophlebitis. 2, 10 The high frequency of UEDVT on the left side shows that this side is used more frequently for venous interventions. Tumours may lead to thrombosis either by direct extension into the veins or by inducing stasis due to compression. Several tumour products or by-products can act as procoagulants which may lead to thromboses in distant locations by activating the coagulation system via factor X. 11 The reliability of CDUSG is affected by the skill of the physician performing the procedure, but it seems to be a highly reliable method for the diagnosis of UEDVT. It is a specific diagnostic tool that detects the presence or absence of blood flow. 12 The sensitivity of CDUSG in the diagnosis of UEDVT has been reported to reach 100%, but decreases in the diagnosis of distal arm and intrathoracic DVTs. 13 Its sensitivity has been demonstrated to be 90.4% for the subclavian vein, 95% for the axillary vein and 83.3% for the brachial vein and its distal branches. 13 In the present study, the sensitivity for determining the presence of UEDVT was 100%, which is consistent with other studies. CDUSG is an excellent alternative to venography, as it is an inexpensive, easy-to-perform, repeatable, non-ionizing and non-invasive method. 4,12 -14 Another advantage of CDUSG when compared with other methods, including venography, is its ability to determine involvement of the jugular venous system during the same session. 4 This is especially important in cases of superior vena cava syndrome or thrombosis due to malpositioning and entrance of a subclavian catheter into the jugular vein.
Treatment of UEDVT may include symptomatic treatment such as elevation and cuff use, the use of anticoagulants and thrombolytic agents, or aggressive treatments such as surgery. 8, 11 The preferred treatment is the combination of a LMWH followed by oral anticoagulants for at least 3 -6 months. 15, 16 LMWHs are derived from standard unfractionated heparins (UFHs) by chemical or enzymatic depolarization. They bind less strongly to plasma proteins, macrophages, endothelial cells, thrombocytes and osteoblasts than UFHs, and are excreted via the renal route. The dose-response relationship and efficacy period may therefore be predicted more precisely. 17 The antithrombotic effects of LMWHs (anti-factor Xa) are more potent than their anticoagulant effects (antifactor IIa, affecting the activated thromboplastin time and the thrombin time). They are, therefore, associated with fewer bleeding complications. The present study showed a very good response to treatment, with lysis being observed in more than 90% of patients. LMWHs are more expensive than standard heparins, but are likely to be cost-effective due to the shorter period of hospitalization required and reduced need for laboratory monitoring. 18 Furthermore, randomized trials have shown that 5 days of LMWH therapy is sufficient for treating venous thrombosis; both the duration and the cost of treatment is reduced compared with standard heparin. 15, 19, 20 These studies also demonstrate that outpatient treatment for DVT with LMWHs is efficacious, well tolerated and cost effective. It is associated with early mobilization, an early return to daily activities and work, and improved quality of life. In the present study, out-patient treatment was established successfully in 77.8% of the patients. Studies
of warfarin use in UEDVT showed that lower doses achieving an INR value of 2 -2.5 are safer than, or as effective as, higher doses. 16, 21 
Conclusion
The increased placement of catheters via the venous system of the upper extremity, mainly for interventional treatments, has greatly increased the frequency of UEDVT. Symptomatic UEDVT is associated with thrombophilic conditions, thoracic malignancies, subclavian vein catheterization or peripheral vein route usage, excessive effort and trauma. Diagnostic imaging methods have an important role in diagnosing UEDVT and evaluating treatment efficacy. CDUSG is a non-invasive, easy-to-perform, repeatable and relatively inexpensive method, and is therefore the preferred diagnostic tool in cases of UEDVT. Treatment of UEDVT aims to relieve symptoms, enable an early return to daily activities, avoid recurrences and limit the duration and cost of the therapy. LMWHs should be preferred over standard heparin due to their ease of use, efficacy and decreased risk of bleeding. 
